Targeting aldose reductase for the treatment of cancer

Current Cancer Drug Targets

Volumn 11, Issue 5, 2011, Pages 560-571

  Tammali, R ^a   Srivastava, S K ^a   Ramana, K V ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Aldose reductase; Cancer and NF B; Inflammation; Oxidative stress

Indexed keywords

ACETIC ACID DERIVATIVE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CHEMOKINE; CIGARETTE SMOKE; CISPLATIN; CYCLOOXYGENASE 2; CYTOKINE; DIESEL FUEL; EPALRESTAT; FIDARESTAT; GALACTITOL; GLUCOSE; GROWTH FACTOR; IDITOL DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PONALRESTAT; RANIRESTAT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUCCINIMIDE; SUGAR PHOSPHATE; TOLRESTAT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ZENARESTAT; ZOPOLRESTAT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ALCOHOL LIVER CIRRHOSIS; ANGIOGENESIS; ANTIOXIDANT ACTIVITY; ASTHMA; ATHEROSCLEROSIS; BACTERIAL INFECTION; BREAST CANCER; CACHEXIA; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CATARACT; CATARACTOGENESIS; CELL ADHESION; CELL DAMAGE; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; CONGESTIVE HEART FAILURE; CYTOTOXICITY; DETOXIFICATION; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RESISTANCE; DRUG TREATMENT FAILURE; EMBRYO DEVELOPMENT; ENZYME INACTIVATION; FETUS LIVER; GARLIC; GASTRITIS; GENE MUTATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEPATITIS; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPERSENSITIVITY; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; KERATINIZATION; LIPID PEROXIDATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LUNG CANCER; MENTAL STRESS; METASTASIS; MYCOSIS; NEOPLASM; NERVE CONDUCTION; NONHUMAN; OBESITY; OSMOSIS; OVARY CANCER; OXIDATIVE STRESS; PHYSICAL STRESS; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RADIOSENSITIVITY; RED MEAT; RESTENOSIS; REVIEW; RISK FACTOR; SEPSIS; SQUAMOUS CELL CARCINOMA; SWELLING; TEA; TUMOR GROWTH; TUMOR RECURRENCE; ULCERATIVE COLITIS; UPREGULATION; UTERINE CERVIX CANCER; VASCULITIS; VIRUS INFECTION;

EID: 79958120421     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911795655958     Document Type: Review

References (113)

1. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug. Discov. 2009, 8, 579-591.
2. Suzuki, K. Anti-oxidants for therapeutic use: why are only a few drugs in clinical use? Adv. Drug Deliv. Rev. 2009, 61, 287-289.
3. Chan, E. C.; Jiang, F.; Peshavariya, H. M.; Dusting, G. J. Regulation of cell proliferation by NADPH oxidase-mediated signaling: potential roles in tissue repair, regenerative medicine and tissue engineering. Pharmacol. Ther. 2009, 122, 97-108.
4. Lau, A. T.; Wang, Y.; Chiu, J. F. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J. Cell Biochem. 2008, 104, 657-667.
5. Nair, U.; Bartsch, H.; Nair, J. Lipid peroxidation-induced DNA damage in cancer-prone inflammatory diseases: a review of published adduct types and levels in humans. Free Radic. Biol. Med. 2007, 43, 1109-1120.
6. Negre-Salvayre, A.; Coatrieux, C.; Ingueneau, C.; Salvayre, R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br. J. Pharmacol. 2008, 153, 6-20.
7. Bartsch, H.; Nair, J. Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect. Prev. 2004, 28, 385-391.
8. Rao, P. V.; Maddala, R.; John, F.; Zigler, J. S. Jr. Expression of nonphagocytic NADPH oxidase system in the ocular lens. Mol. Vis. 2004, 10, 112-121.
9. Vaquero, E. C.; Edderkaoui, M.; Pandol, S. J.; Gukovsky, I.; Gukovskaya, A. S. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer ells. J. Biol. Chem. 2004, 279, 34643-34654.
10. Tacchini, L.; Dansi, P.; Matteucci, E.; Desiderio, M. A. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 2001, 22, 1363-1371.
11. Hoozemans, J. J.; Rozemuller, A. J.; Veerhuis, R.; Eikelenboom, P. Immunological aspects of alzheimer's disease: therapeutic implications. BioDrugs 2001, 15, 325-337.
12. Márton, I.; J.; Kiss, C. Protective and destructive immune reactions in apical periodontitis. Oral Microbiol. Immunol. 2000, 15, 139-150.
13. Khatami, M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem. Biophys. 2009, 55, 55-79.
14. Gauldie, J. Inflammation and the aging process: devil or angel. Nutr. Rev. 2007, 65, S167-S169.
15. Benjamim, C. F.; Hogaboam, C. M.; Kunkel, S. L. The chronic consequences of severe sepsis. J. Leukoc. Biol. 2004, 75, 408-412.
16. Andreasen, A. S.; Krabbe, K. S.; Krogh-Madsen, R.; Taudorf, S.; Pedersen, B. K.; Møller, K. Human endotoxemia as a model of systemic inflammation. Curr. Med. Chem. 2008, 15, 1697-1705.
17. Sutcliffe, A. M.; Clarke, D. L.; Bradbury, D. A.; Corbett, L. M.; Patel, J. A.; Knox, A. J. Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NF-kappaB and AP-1. Br. J. Pharmacol. 2009, 157, 436-450.
18. Kobliakov, V. A. Mechanisms of tumor promotion by reactive oxygen species. Biochemistry (Mosc). 2010, 75, 675-685.
19. Naugler, W. E.; Karin, M. NF-kappaB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 2008, 18, 19-26.
20. Solinas, G.; Marchesi, F.; Garlanda, C.; Mantovani, A.; Allavena, P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev. 2010, 29, 243-248.
21. Hayakawa, M.; Miyashita, H.; Sakamoto, I.; Kitagawa, M.; Tanaka, H.; Yasuda, H.; Karin, M.; Kikugawa, K. Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J. 2003, 22, 3356-3366.
22. Gupta, G. P.; Massague, J. Cancer metastasis: building a framework, Cell 2006, 127, 79-95.
23. Karin, M.; Lawrence, T.; Nizet, V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124, 823-835.
24. Ramana, K. V.; Bhatnagar, A.; Srivastava, S.; Yadav, U. C.; Awasthi, S.; Awasthi, Y. C.; Srivastava, S. K. Mitogenic responses of vascular smooth muscle cells to lipid peroxidation-derived aldehyde 4-hydroxy-trans-2-nonenal (HNE): role of aldose reductase-catalyzed reduction of the HNE-glutathione conjugates in regulating cell growth. J. Biol. Chem. 2006, 281, 17652-17660.
25. Tammali, R.; Ramana, K. V.; Singhal, S. S.; Awasthi, S.; Srivastava, S. K. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res. 2006, 66, 9705-9713.
26. Tammali, R.; Ramana, K. V.; Srivastava, S. K. Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells. Cancer Lett. 2007, 252, 299-306.
27. Srivastava, S. K.; Ramana, K. V.; Bhatnagar, A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 2005, 26, 380-392.
28. Hers, H. G. The mechanism of the transformation of glucose in fructose in the seminal vesicles. Biochim. Biophys. Acta 1956, 22, 202-203.
29. van Heyningen, R. Formation of polyols by the lens of the rat with 'sugar' cataract. Nature 1959, 468, 194-195.
30. Varma, S. D.; Mizuno, A.; Kinoshita, J. H. Diabetic cataracts and flavonoids. Science 1977, 195, 205-206.
31. Kinoshita, J. H.; Kador, P.; Catiles, M. Aldose reductase in diabetic cataracts. JAMA 1981, 246, 257-261.
32. Srivastava, S. K.; Petrash, J. M.; Sadana, I. J.; Ansari, N. H.; Partridge, C. A. Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors. Curr. Eye Res. 1982, 2, 407-410.
33. Srivastava, S. K.; Ansari, N. H. Prevention of sugar-induced cataractogenesis in rats by butylated hydroxytoluene. Diabetes 1988, 37, 1505-1508.
34. Ruef, J.; Liu, S. Q.; Bode, C.; Tocchi, M.; Srivastava, S.; Runge, M. S.; Bhatnagar, A. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1745-1752.
35. Donohue, P. J.; Alberts, G. F.; Hampton, B. S.; Winkles, J. A. A delayed-early gene activated by fibroblast growth factor-1 encodes a protein related to aldose reductase. J. Biol. Chem. 1994, 269, 8604-8609.
36. Tawata, M.; Ohtaka, M.; Hosaka, Y.; Onaya, T. Aldose reductase mRNA expression and its activity are induced by glucose in fetal rat aortic smooth muscle (A10) cells. Life Sci. 1992, 51, 719-726.
37. Seo, H. G.; Nishinaka, T.; Yabe-Nishimura, C. Nitric oxide upregulates aldose reductase expression in rat vascular smooth muscle cells: a potential role for aldose reductase in vascular remodeling. Mol. Pharmacol. 2000, 57, 709-717.
38. Ramana, K. V.; Chandra, D.; Srivastava, S.; Bhatnagar, A.; Aggarwal, B. B.; Srivastava, S. K. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem. 2002, 277, 32063-32070. http://edrv.endojournals.org/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=277/35/32063.
39. Yadav, U. C.; Ramana, K. V.; Aguilera-Aguirre, L.; Boldogh, I.; Boulares, H. A.; Srivastava, S. K. Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice. PLoS One 2009, 4, e6535.
40. Ramana, K, V.; Fadl, A. A.; Tammali, R.; Reddy, A. B.; Chopra, A. K.; Srivastava, S. K. Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages. J. Biol. Chem. 2006, 281, 33019-33029.
41. Ramana, K. V.; Reddy, A. B.; Tammali, R.; Srivastava, S. K. Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages. Free Radic. Biol. Med. 2007, 42, 1290-1302.
42. Tammali, R.; Reddy, A. B.; Ramana, K. V.; Petrash, J. M.; Srivastava, S. K. Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. Carcinogenesis 2009, 30, 799-807.
43. Ravindranath, T. M.; Mong, P. Y.; Ananthakrishnan, R.; Li, Q.; Quadri, N.; Schmidt, A. M.; Ramasamy, R.; Wang, Q. Novel role for aldose reductase in mediating acute inflammatory responses in the lung. J. Immunol. 2009, 183, 8128-8137.
44. Jianghua, L.; Gebo, W.; Deliang, C. Aldo-Keto reductase family 1 member B1 inhibitors: Old drugs with new perspectives. Recent Pat. Anti-Canc. 2009, 4, 246-253.
45. Schemmel K. E.; Rosalyn, S.; Padiyara, R. S.; D'Souza, J. J. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J. Diabetes Complications 2010, 24, 354-360.
46. Cheung, A. K.; Fung, M. K.; Lo, A. C. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis and glial reactivation in the retina of db/db mice. Diabetes 2005, 54, 3119-3125.
47. Yamaoka, T.; Nishimura, C.; Yamashita, K. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 1995, 38, 255-261.
48. Hotta, N.; Toyota, T.; Matsuoka, K. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy. Diabetes Care 2001, 24, 1776-1782.
49. Asano, T.; Saito, Y.; Kawakami, M. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860). J. Diabetes Complicat. 2004, 18, 336-342.
50. Singh, R.; White, M. A.; Ramana, K. V.; Petrash, J. M.; Watowich, S. J.; Bhatnagar, A.; Srivastava, S. K. Structure of a glutathione conjugate bound to the active site of aldose reductase. Proteins 2006, 64, 101-110.
51. Ramana, K. V.; Dixit, B. L.; Srivastava, S.; Balendiran, G. K.; Srivastava, S. K.; Bhatnagar, A. Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry 2000, 39, 12172-12180.
52. Zeindl-Eberhart, E.; Jungblut, P. R.; Otto, A.; Rabes, H. M. Identification of tumor-associated protein variants during rat hepatocarcinogenesis. Aldose reductase. J. Biol. Chem. 1994, 269, 14589-14594.
53. Lefrançois-Martinez, A. M.; Bertherat, J.; Val, P.; Tournaire, C.; Gallo-Payet, N.; Hyndman, D.; Veyssière, G.; Bertagna, X.; Jean, C.; Martinez, A. Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 2004, 89, 3010-3019.
54. Saraswat, M.; Mrudula, T.; Kumar, P. U.; Suneetha, A.; Rao, T. S.; Srinivasulu, M.; Reddy, B.Overexpression of aldose reductase in human cancer tissues. Med. Sci. Monit. 2006, 12, CR525-529.
55. Yoshitake, H.; Takahashi, M.; Ishikawa, H.; Nojima, M.; Iwanari, H.; Watanabe, A.; Aburatani, H.; Yoshida, K.; Ishi, K.; Takamori, K.; Ogawa, H.; Hamakubo, T.; Kodama, T.; Araki, Y. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int. J. Gynecol. Cancer 2007, 17, 1300-1306.
56. Tanimoto, T.; Sato, S.; Kador, P. F. Purification and properties of aldose reductase and aldehyde reductase from EHS tumor cells. Biochem. Pharmacol. 1990, 39, 445-453.
57. Hung, H. S.; Wu, W. J.; Cheng, Y. W.; Wu, T. C.;. Chang, K. L.; Lee, H. Association of cooking oil fumes exposure with lung cancer: involvement of inhibitor of apoptosis proteins in cell survival and proliferation in vitro. Mutat. Res. 2007, 628, 107-716.
58. Horton, N. D.; Mamiya, B. M.; Kehrer, J. P. Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Toxicology 1997, 122, 111-122.
59. Yu, H.; Pan, C.; Zhao, S.; Wang, Z.; Zhang, H.; Wu, W. Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed. Pharmacother. 2008, 62, 366-372.
60. Huang, C. S.; Fan, Y. E.; Lin, C. Y.; Hu, M. L. Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1. J. Nutr. Biochem. 2007, 18, 449-456.
61. Zafarullah, M.; Li, W. Q.; Sylvester, J.; Ahmad, M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol. Life Sci. 2003, 60, 6-20.
62. Yang, C. S.; Maliakal, P.; Meng, X. Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 25-54.
63. Morin, P. Jr.; Ni, Z.; McMullen, D. C.; Storey, K. B. Expression of Nrf2 and its downstream gene targets in hibernating 13-lined ground squirrels, Spermophilus tridecemlineatus. Mol. Cell Biochem. 2008, 312, 121-129.
64. Chew, E. H.; Nagle, A. A.; Zhang, Y.; Scarmagnani, S.; Palaniappan, P.; Bradshaw, T. D.; Holmgren, A.; Westwell, A. D. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radic. Biol. Med. 2010, 48, 98-111.
65. Kang, E. S.; Kim, G. H.; Kim, H. J.; Woo, I. S.; Ham, S. A.; Jin, H.; Kim, M. Y.; Kim, H. J.; Lee, J. H.; Chang, K. C.; Seo, H. G.; Hwang, J. Y. Nrf2 regulates curcumin-induced aldose reductase expression indirectly via nuclear factor-kappaB. Pharmacol. Res. 2008, 58, 15-21.
66. Liao, B. C.; Hsieh, C. W.; Liu, Y. C.; Tzeng, T. T.; Sun, Y. W.; Wung, B. S. Cinnamaldehyde inhibits the tumor necrosis factoralpha-induced expression of cell adhesion molecules in endothelial cells by suppressing NF-kappaB activation: effects upon IkappaB and Nrf2. Toxicol. Appl. Pharmacol. 2008, 229, 161-171.
67. Kang, E. S.; Woo, I. S.; Kim, H. J.; Eun, S. Y.; Paek, K. S.; Kim, H. J.; Chang, K. C.; Lee, J. H.; Lee, H. T.; Kim, J. H.; Nishinaka, T.; Yabe-Nishimura, C.; Seo, H. G. Up-regulation of aldose reductase expression mediated by phosphatidylinositol 3-kinase/Akt and Nrf2 is involved in the protective effect of curcumin against oxidative damage. Free Radic. Biol. Med. 2007, 43, 535-545.
68. Nishinaka, T.; Yabe-Nishimura, C. Transcription factor Nrf2 regulates promoter activity of mouse aldose reductase (AKR1B3) gene. J. Pharmacol. Sci. 2005, 97, 43-51.
69. Jemal. A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
70. Kim, Y. Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J. Nutr. 2005, 135, 2703-2709.
71. Weinstein, I. B. Nonmutagenic mechanisms in carcinogenesis: role of protein kinase C in signal transduction and growth control. Environ. Health Perspect. 1991, 93, 175-179.
72. Liu, Z. X.; Kiran, R. P.; Bennett, A. E.; Ni, R. Z; Shen, B. Diagnosis and management of dysplasia and cancer of the ileal pouch in patients with underlying inflammatory bowel disease. Cancer 2011 doi: 10.1002/cncr.25886.
73. 2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 2000, 19, 5517-1524.
74. Nakao, S.; Ogata, Y.; Yamamoto, Y.; Furuyama, S.; Sugiya, H. Platelet-derived growth factor-induced arachidonic acid release for enhancement of prostaglandin E(2) synthesis in human gingival fibroblasts pretreated with interleukin-1ß. J. Cell Biochem. 2004, 92, 579-590.
75. Rao, C. V.; Reddy, B. S. NSAIDs and chemoprevention. Curr. Cancer Drug Targets 2004, 4, 29-42.
76. Swamy, M. V.; Herzog, C. R.; Rao, C. V. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res. 2003, 63, 5239-5242.
77. Schetter, A. J.; Heegaard, N. H.; Harris, C. C. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31, 37-49.
78. Hansen, R.; Thomson, J. M.; El-Omar, E. M.; Hold, G. L. The role of infection in the aetiology of inflammatory bowel disease. J. Gastroenterol. 2010, 45, 266-276.
79. Pardee, A.B.; Li, C.J.; Reddy, G.P. Regulation in S phase by E2F. Cell Cycle 2004, 3, 1091-2004.
80. Ramana, K. V.; Tammali, R.; Srivastava, S. K. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells. Mol. Cancer Ther. 2010, 9, 813-824.
81. Gustot, T.; Durand, F.; Lebrec, D.; Vincent, J. L.; Moreau, R. Severe sepsis in cirrhosis. Hepatology 2009, 50, 2022-2033.
82. Samanta, B. K.; Chandra, N. C.; Ghosh, S.; Mukherjee, K. L. Aldose metabolism in developing human fetal brain and liver. Experientia 1984, 40, 1420-1422.
83. Scuric, Z.; Stain, S. C.; Anderson, W. F.; Hwang, J. J. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998, 27, 943-950.
84. Takahashi, M.; Hoshi, A.; Fujii, J.; Miyoshi, E.; Kasahara, T.; Suzuki, K.; Aozasa, K.; Taniguchi, N. Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma. Jpn. J. Cancer Res. 1996, 87, 337-341.
85. Takahashi, M.; Fujii, J.; Miyoshi, E.; Hoshi, A.; Taniguchi, N. Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. Int. J. Cancer 1995, 62, 749-754.
86. Ibrahim, S. S.; Nassar, N. N. Diallyl sulfide protects against Nnitrosodiethylamine-induced liver tumorigenesis: role of aldose reductase. World J. Gastroenterol. 2008, 40, 6145-6153.
87. Ockenga, J.; Valentini, L. Review article: anorexia and cachexia in gastrointestinal cancer. Aliment Pharmacol. Ther. 2005, 22, 583-594.
88. Saini, A.; Faulkner, S.; Al-Shanti, N.; Stewart, C. Powerful signals for weak muscles. Ageing Res. Rev. 2009, 8, 251-267.
89. Michael, J.; Tisdale. Cancer cachexia. Langenbecks Arch. Surg. 2004, 389, 299-305.
90. Lorite, M. J.; Cariuk, P.; Tisdale, M. J. Induction of muscle protein degradation by a tumour factor. Br. J. Cancer 1997, 76, 1035-1040.
91. Li, Y. P.; Reid, M. B. NF-kB mediates the protein loss induced by TNF-a in differentiated skeletal muscle myotubes. Am. J. Physiol. 2000, 279, R1165-R1170.
92. Berg, M.; Fraker, D. L.; Alexander, H. R. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine 1994, 6, 425-432.
93. Fujita, J.; Tsujinaka, T.; Yano, M. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinomabearing mice with modulation of lysosomal and ATPubiquitindependent proteolytic pathways. Int. J. Cancer 1996, 68, 637-643.
94. Watchorn, T. M.; Waddell, I. D.; Dowidar, N.; Ross, J. A. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-kB and STAT3. FASEB J. 2001, 15, 562-564.
95. Wyke, S. M.; Russell, S. T.; Tisdale, M. J. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NFkappaB activation. Br. J. Cancer 2004, 91, 1742-1750.
96. Kawamura, I.; Lacey, E.; Yamamoto, N.; Sakai, F.; Takeshita, S.; Inami, M.; Nishigaki, F.; Naoe, Y.; Tsujimoto, S.; Manda, T.; Shimomura, K.; Goto, T. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice. Anticancer Res. 1999, 19, 4105-4111.
97. Kawamura, I.; Lacey, E.; Inami, M.; Nishigaki, F.; Naoe, Y.; Tsujimoto, S.; Manda, T.; Goto, T. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI. Anticancer Res. 1999, 19, 4091-4097.
98. Nadkar, A.; Pungaliya, C.; Drake, K.; Zajac, E.; Singhal, S. S.; Awasthi, S. Therapeutic resistance in lung cancer. Expert Opin. Drug Metab. Toxicol. 2006, 2, 753-777.
99. Baguley, B. C. Multidrug resistance in cancer. Methods Mol. Biol. 2010, 596, 1-14.
100. Liu, F. S. Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review. Taiwan J. Obstet. Gynecol. 2009, 48, 239-244.
101. Giménez-Bonafé, P.; Tortosa, A.; Pérez-Tomás, R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr. Cancer Drug Targets 2009, 9, 320-340.
102. Dean, M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia 2009, 14, 3-9.
103. Hait, W. N.; Hambley, T. W. Targeted cancer therapeutics. Cancer Res. 2009, 69, 1263-1267.
104. Bando, T.; Fujimura, M.; Kasahara, K.; Shibata, K.; Shirasaki, H.; Heki, U.; Iwasa, K.; Ueda, A.; Tomikawa, S.; Matsuda, T. Exposure to sorbitol induces resistance to cisplatin in human nonsmall-cell lung cancer cell lines. Anticancer Res. 1997, 17, 3345-3348.
105. Balendiran, G. K.; Martin, H. J.; El-Hawari, Y.; Maser, E. Cancer biomarker AKR1B10 and carbonyl metabolism. Chem. Biol. Interact. 2009, 178, 134-137.
106. Verma, M.; Martin, H. J.; Haq, W.; O'Connor, T. R.; Maser, E.; Balendiran, G. K. Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur. J. Pharmacol. 2008, 584, 213-221.
107. Hasuike, Y.; Moriguchi, R.; Hata, R.; Miyagawa, K.; Kuragano, T.; Aizawa, M.; Yamamoto, S.; Yanase, K.; Izumi, M.; Tanimoto, T.; Nakanishi, T. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis. Am. J. Nephrol. 2007, 7, 622-629.
108. Lee, Y. S.; Paek, K. S.; Kang, E. S.; Jang, H. S.; Kim, H. J.; Kang, Y. J.; Kim, J. H.; Lee, H. T.; Lee, J. H.; Chang, K. C.; Nishinaka, T.; Seo, H. G. Involvement of nuclear factor kappaB in upregulation of aldose reductase gene expression by 12-Otetradecanoylphorbol-13-acetate in HeLa cells. Int. J. Biochem. Cell Biol. 2005, 37, 2297-2309.
109. Kamiya, H.; Nakamura, J.; Hamada, Y.; Nakashima, E.; Naruse, K.; Kato, K.; Yasuda, Y.; Hotta, N. Polyol pathway and protein kinase C activity of rat Schwannoma cells. Diabetes Metab. Res. Rev. 2003, 19, 131-139.
110. Lee, E. K.; Regenold, W. T.; Shapiro, P. Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anticancer Drugs 2002, 13, 859-868.
111. Lee, K. W.; Ko, B. C.; Jiang, Z.; Cao, D.; Chung, S. S. Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 2001, 12, 129-132.
112. Ramana, K. V.; Srivastava, S. K. Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int. J. Biochem. Cell Biol. 2010, 42, 17-20.
113. Srivastava, S. K; Yadav, U. C.; Reddy, A. B.; Saxena, A.; Tammali, R.; Shoeb, M.; Ansari, N. H.; Bhatnagar, A.; Petrash, M. J.; Srivastava, S.; Ramana, K. V. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem. Biol. Interact. 2011 doi:10.1016/j.cbi.2011.02.023.